Medical Use
Indications and Usage
Krazati is a groundbreaking inhibitor targeting the RAS GTPase family, offering a promising treatment for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This medication is intended for patients who have previously received at least one systemic therapy, as verified by an FDA-approved test. Notably, this indication has received accelerated approval based on the objective response rate (ORR) and duration of response (DOR). Further clinical benefit may need to be confirmed in additional trials.
Dosage and Administration
- (i)Recommended Dosage: 600 mg taken orally twice daily.
- (ii)Administration: Tablets should be swallowed whole, with or without food.
Contraindications
Warning & Precautions
- -Gastrointestinal Adverse Reactions: Monitor patients closely for symptoms such as diarrhea, nausea, and vomiting. Provide appropriate supportive care as needed. Adjust the dose based on symptom severity.
- -QTc Interval Prolongation: Avoid using Krazati with products known to prolong the QTc interval. Regularly monitor ECG and electrolytes in at-risk patients or those on QT-prolonging medications. Adjust the dose or discontinue treatment as necessary.
- -Hepatotoxicity: Conduct liver laboratory tests before starting Krazati, monthly for the first three months, and as clinically indicated. Depending on the severity of hepatotoxicity, dose adjustments, temporary suspension, or permanent discontinuation may be necessary.
- -Interstitial Lung Disease / Pneumonitis: Monitor for new or worsening respiratory symptoms. If suspected, temporarily withhold Krazati and discontinue if no alternative causes of ILD/pneumonitis are identified.
Adverse Reactions
- -Common Adverse Reactions (≥ 25%): Nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite.
- -Common Grade 3 or 4 Laboratory Abnormalities (≥ 2%): Decreased lymphocytes, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, decreased leukocytes, decreased neutrophils, and increased alkaline phosphatase.
Drug Interactions:
For comprehensive details on clinically significant drug interactions with Krazati, please consult the full prescribing information. Key points include avoiding concurrent use with strong CYP3A4 inducers or inhibitors, sensitive CYP3A4 substrates, sensitive CYP2C9 or CYP2D6 substrates, P-gp substrates, and drugs that prolong the QT interval. These precautions are essential to ensure the safety and effectiveness of the treatment.
Documentation Availability
Documents required to import Krazati to India?
Krazati (adagrasib) tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Krazati from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is Krazati used for?
Krazati is prescribed for treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) in adults who have previously undergone systemic therapy.
How does Krazati work?
Krazati functions by inhibiting the KRAS G12C mutation, thereby slowing down the growth of cancer cells.
Who is eligible for Krazati?
Adults diagnosed with KRAS G12C-mutated NSCLC through an FDA-approved test and who have received prior therapy are eligible for Krazati.
What are common side effects?
Common side effects include nausea, diarrhea, fatigue, and more. It’s important to discuss these with your healthcare provider.
Is Krazati available in India?
Yes, Krazati is available in India with a valid doctor’s prescription and the necessary documentation.
Is Krazati FDA approved?
Krazati received FDA approval in 2022.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
